Revolution Medicines Rated D Amid Acquisition Talks with Merck
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 25 2026
0mins
Should l Buy RVMD?
Revolution Medicines Inc. has seen its stock price decline by 5.00%, hitting a 5-day low amid broader market weakness, with the Nasdaq-100 down 1.28% and the S&P 500 down 1.26%.
The company received a D rating for earnings momentum, indicating a notable decline in earnings expectations that could lead to stock price volatility. Additionally, Merck is reportedly in talks to acquire Revolution Medicines for up to $32 billion, which could significantly enhance Merck's oncology portfolio if the deal goes through. This combination of weak earnings momentum and potential acquisition discussions is creating a complex environment for investors.
As the earnings season progresses, the pressure on Revolution Medicines' stock may lead to increased volatility, especially with the ongoing acquisition talks. Investors will be closely monitoring both the earnings reports and the outcome of the acquisition discussions.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RVMD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RVMD
Wall Street analysts forecast RVMD stock price to fall
20 Analyst Rating
20 Buy
0 Hold
0 Sell
Strong Buy
Current: 98.640
Low
67.00
Averages
86.00
High
147.00
Current: 98.640
Low
67.00
Averages
86.00
High
147.00
About RVMD
Revolution Medicines, Inc. is a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers. The Company’s research and development pipeline comprises RAS(ON) inhibitors that bind directly to RAS variants, which it refers to as RAS(ON) Inhibitors, and RAS companion inhibitors that target key nodes in the RAS pathway or associated pathways, which it refers to as RAS Companion Inhibitors. Its RAS(ON) Inhibitors are designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or in combination with RAS Companion Inhibitors or other therapeutic agents. The company’s RAS(ON) inhibitors are daraxonrasib (RMC-6236), an RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), an RAS(ON) G12C-selective inhibitor; and zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor, are in clinical development. The Company’s pipeline also focuses on RAS(ON) mutant-selective inhibitors, including RMC-0708 (Q61H) and RMC-8839 (G13C).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Form 144: Revolution Medicines (RVMD.US) Executive Plans to Sell $3.58 Million in Common Stock
Stock Sale Announcement: Revolution Medicines plans to sell 37,450 shares of its common stock on March 25, 2026.
Market Value: The total market value of the shares being sold is approximately $3.58 million.
See More
DAFNA Capital Management Reduces Stake in Biotechnology ETF
- Share Reduction: DAFNA Capital Management sold 34,405 shares of iShares Biotechnology ETF (IBB) in Q4 2025, resulting in a $3.31 million decrease in quarter-end position value, reflecting both trading activities and stock price fluctuations.
- Asset Management Impact: This transaction reduced IBB's share of DAFNA's 13F reportable assets to 2.67%, indicating that IBB is no longer among the fund's top five holdings, which highlights its diminishing significance in the investment portfolio.
- Market Performance: As of February 17, 2026, IBB's price stood at $174.02, marking a 27.2% increase over the past year, with an alpha of 15.84 percentage points compared to the S&P 500, showcasing the ETF's strong performance in the biotechnology sector.
- Investment Strategy: The iShares Biotechnology ETF primarily invests in large, commercial-stage biotech companies and employs a passive investment strategy aimed at efficient index replication and liquidity management, although it remains sensitive to interest rates and investor risk appetite.
See More
DAFNA Capital Management Reduces Stake in iShares Biotechnology ETF
- Stake Reduction Details: According to an SEC filing dated February 17, 2026, DAFNA Capital Management reduced its stake in the iShares Biotechnology ETF by 34,405 shares during Q4 2025, resulting in a $3.31 million decrease in position value, highlighting the impact of market fluctuations on the portfolio.
- Asset Allocation Shift: Following the sale, the iShares Biotechnology ETF now comprises 2.67% of DAFNA Capital's 13F reportable assets, indicating a relative decline in the ETF's significance within the overall investment strategy.
- Top Holdings Overview: As of February 17, 2026, DAFNA's top five holdings include NASDAQ:RVMD at $48.15 million (11.3% of AUM) and NYSEMKT:XBI at $41.03 million (9.7% of AUM), reflecting a continued focus on large-cap biotech firms in its investment approach.
- ETF Performance Analysis: As of February 17, 2026, the iShares Biotechnology ETF was priced at $174.02, up 27.2% over the past year, demonstrating stable performance in the biotech sector, though it remains sensitive to shifts in market risk appetite for growth-oriented healthcare stocks.
See More
RBC Capital Markets Lists 13 Biotechs Likely to Attract Takeover Interest
- Acquisition Potential Analysis: RBC Capital Markets analyst Leonid Timashev highlighted that approximately 85 reports on biotech acquisitions have surfaced since 2021, indicating sustained acquisition interest in the sector, particularly for companies like Revolution Medicines (RVMD), Ascendis Pharma (ASND), and Arrowhead Pharma (ARWR).
- Media Impact Variability: Timashev analyzed M&A commentary from four major publications and found that Betaville's hit rate was only 20%-30%, while others achieved hit rates of 60%-70%, demonstrating significant differences in the accuracy and influence of various media on acquisition news.
- Investment Return Potential: Reports from Bloomberg and the Financial Times showed a median return of 27% over 30 days, with the FT's return soaring to 70% over 90 days, underscoring the profound impact of M&A activities on investor returns in the biotech sector.
- Potential Acquirers List: Timashev also identified Merck (MRK), AbbVie (ABBV), and Bristol Myers Squibb (BMY) as the most likely potential buyers, indicating a rising interest from large pharmaceutical companies in acquiring biotech firms.
See More
REVOLUTION MEDICINES INC: UBS Increases Price Target from $71 to $145
- Price Increase Announcement: Revolution Medicines has raised the target price for its stock from $71 to $145.
- Market Impact: This significant increase reflects the company's positive outlook and potential growth in the market.
See More
Revolution Medicines Q4 2025 Earnings Call Highlights
- Pipeline Progress: Revolution Medicines has made substantial advancements in its RAS(ON) inhibitor pipeline, with four novel investigational drugs undergoing eight Phase III registrational trials and over 2,500 patients treated, indicating the company's potential and competitiveness in oncology.
- Financial Overview: As of Q4 2025, the company reported $2.03 billion in cash and investments, despite R&D expenses rising to $294.9 million year-over-year and a net loss of $364.9 million, reflecting high investments in clinical development and commercial preparations.
- Guidance Adjustment: The company shifted its financial outlook for 2026 from GAAP net loss to GAAP operating expenses, expecting these to range between $1.6 billion and $1.7 billion, highlighting its focus on expanding clinical programs and commercial readiness.
- Market Sentiment Caution: Analysts' scrutiny regarding trial design and interim data suggests a cautious market outlook on the company's future performance, although management expressed confidence in pipeline progress and commercial preparations during the earnings call.
See More
Form 144: Revolution Medicines (RVMD.US) Executive Plans to Sell $3.58 Million in Common Stock
Stock Sale Announcement: Revolution Medicines plans to sell 37,450 shares of its common stock on March 25, 2026.
Market Value: The total market value of the shares being sold is approximately $3.58 million.
See More
DAFNA Capital Management Reduces Stake in Biotechnology ETF
- Share Reduction: DAFNA Capital Management sold 34,405 shares of iShares Biotechnology ETF (IBB) in Q4 2025, resulting in a $3.31 million decrease in quarter-end position value, reflecting both trading activities and stock price fluctuations.
- Asset Management Impact: This transaction reduced IBB's share of DAFNA's 13F reportable assets to 2.67%, indicating that IBB is no longer among the fund's top five holdings, which highlights its diminishing significance in the investment portfolio.
- Market Performance: As of February 17, 2026, IBB's price stood at $174.02, marking a 27.2% increase over the past year, with an alpha of 15.84 percentage points compared to the S&P 500, showcasing the ETF's strong performance in the biotechnology sector.
- Investment Strategy: The iShares Biotechnology ETF primarily invests in large, commercial-stage biotech companies and employs a passive investment strategy aimed at efficient index replication and liquidity management, although it remains sensitive to interest rates and investor risk appetite.
See More
DAFNA Capital Management Reduces Stake in iShares Biotechnology ETF
- Stake Reduction Details: According to an SEC filing dated February 17, 2026, DAFNA Capital Management reduced its stake in the iShares Biotechnology ETF by 34,405 shares during Q4 2025, resulting in a $3.31 million decrease in position value, highlighting the impact of market fluctuations on the portfolio.
- Asset Allocation Shift: Following the sale, the iShares Biotechnology ETF now comprises 2.67% of DAFNA Capital's 13F reportable assets, indicating a relative decline in the ETF's significance within the overall investment strategy.
- Top Holdings Overview: As of February 17, 2026, DAFNA's top five holdings include NASDAQ:RVMD at $48.15 million (11.3% of AUM) and NYSEMKT:XBI at $41.03 million (9.7% of AUM), reflecting a continued focus on large-cap biotech firms in its investment approach.
- ETF Performance Analysis: As of February 17, 2026, the iShares Biotechnology ETF was priced at $174.02, up 27.2% over the past year, demonstrating stable performance in the biotech sector, though it remains sensitive to shifts in market risk appetite for growth-oriented healthcare stocks.
See More
RBC Capital Markets Lists 13 Biotechs Likely to Attract Takeover Interest
- Acquisition Potential Analysis: RBC Capital Markets analyst Leonid Timashev highlighted that approximately 85 reports on biotech acquisitions have surfaced since 2021, indicating sustained acquisition interest in the sector, particularly for companies like Revolution Medicines (RVMD), Ascendis Pharma (ASND), and Arrowhead Pharma (ARWR).
- Media Impact Variability: Timashev analyzed M&A commentary from four major publications and found that Betaville's hit rate was only 20%-30%, while others achieved hit rates of 60%-70%, demonstrating significant differences in the accuracy and influence of various media on acquisition news.
- Investment Return Potential: Reports from Bloomberg and the Financial Times showed a median return of 27% over 30 days, with the FT's return soaring to 70% over 90 days, underscoring the profound impact of M&A activities on investor returns in the biotech sector.
- Potential Acquirers List: Timashev also identified Merck (MRK), AbbVie (ABBV), and Bristol Myers Squibb (BMY) as the most likely potential buyers, indicating a rising interest from large pharmaceutical companies in acquiring biotech firms.
See More
REVOLUTION MEDICINES INC: UBS Increases Price Target from $71 to $145
- Price Increase Announcement: Revolution Medicines has raised the target price for its stock from $71 to $145.
- Market Impact: This significant increase reflects the company's positive outlook and potential growth in the market.
See More
Revolution Medicines Q4 2025 Earnings Call Highlights
- Pipeline Progress: Revolution Medicines has made substantial advancements in its RAS(ON) inhibitor pipeline, with four novel investigational drugs undergoing eight Phase III registrational trials and over 2,500 patients treated, indicating the company's potential and competitiveness in oncology.
- Financial Overview: As of Q4 2025, the company reported $2.03 billion in cash and investments, despite R&D expenses rising to $294.9 million year-over-year and a net loss of $364.9 million, reflecting high investments in clinical development and commercial preparations.
- Guidance Adjustment: The company shifted its financial outlook for 2026 from GAAP net loss to GAAP operating expenses, expecting these to range between $1.6 billion and $1.7 billion, highlighting its focus on expanding clinical programs and commercial readiness.
- Market Sentiment Caution: Analysts' scrutiny regarding trial design and interim data suggests a cautious market outlook on the company's future performance, although management expressed confidence in pipeline progress and commercial preparations during the earnings call.
See More
